The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis

Keyphrases

• Type 2 Diabetes Mellitus (T2DM) 100%
• Liraglutide 100%
• Dialysis 100%
• Continuous Glucose Monitoring 100%
• Glycemic Efficacy 100%
• Hypoglycemic Events 66%
• End-stage Renal Disease 50%
• Dialysis-dependent 50%
• Placebo 33%
• Placebo Groups 33%
• Glucose Variability 33%
• AIMS™ 16%
• Insulin 16%
• Glucose Values 16%
• Blinded Treatment 16%
• Coefficient of Variation 16%
• Maximum Tolerated Dose 16%
• Glycated Hemoglobin A1c 16%
• Linear Mixed Model 16%
• Antidiabetic Treatment 16%
• Hypoglycemia Risk 16%
• Medtronic 16%
• Monitoring Data 16%
• Group Standard 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Insulin Dependent Diabetes Mellitus 100%
• Liraglutide 100%
• Antidiabetic Agent 83%
• Placebo 66%
• End Stage Renal Disease 50%
• Hypoglycemia 16%
• Hemoglobin A1c 16%
• Maximum Tolerated Dose 16%
• Mixed Model 16%